AN2 Therapeutics, Inc.
HealthcareNASDAQ:ANTX · NASDAQ Global Select
+$0.29 today
Vol 0.19M · Avg 0.30M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $53.5M |
| Short-term Investments | $31.8M |
| Other Current | $2.2M |
| Total Current Assets | $87.5M |
| Total Assets | $87.5M |
Analysis
Selected assets total $87.5M for Latest. The largest visible component is Cash & Equivalents at $53.5M, about 61.1% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $19.9M -6.6% | $21.4M +36.5% | $15.6M -42.5% | $27.2M +125.0% | $12.1M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $38.1M -38.9% | $62.3M -32.1% | $91.6M +33.1% | $68.8M +48.2% | $46.5M | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $900.0K +200.0% | $300.0K -78.6% | $1.4M | $0 | $0 | $533.8M | $399.4M | -$1.7B |
| Inventory | $0 | $0 | $0 | $0 | $0 | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $1.0M -55.8% | $2.3M -27.0% | $3.2M +25.4% | $2.6M +65.2% | $1.6M | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $59.9M -30.5% | $86.3M -21.9% | $110.5M +12.1% | $98.6M +64.1% | $60.1M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $0 | $0 | $0 -100.0% | $53.0K | $0 | $1.2B | $1.5B | $687.8M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $2.0M -59.9% | $5.0M -81.5% | $27.2M +744.8% | $3.2M -7.7% | $3.5M | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $0 -100.0% | $804.0K -22.9% | $1.0M +56.4% | $667.0K -61.3% | $1.7M | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $2.0M -65.4% | $5.8M -79.4% | $28.2M +616.9% | $3.9M -24.4% | $5.2M | -$15.3B | $14.8B | $11.3B |
| Total Assets | $62.0M -32.7% | $92.1M -33.6% | $138.7M +35.3% | $102.6M +57.0% | $65.3M | $13.3B | $11.9B | $10.6B |
| Account Payables | $3.0M -8.9% | $3.3M +24.0% | $2.7M +26.1% | $2.1M +99.6% | $1.1M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $0 | $0 | $0 | $0 | $0 | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 | $0 | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $5.7M +131.0% | $2.5M -47.4% | $4.7M +78000.0% | $6.0K -98.2% | $330.0K | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $8.7M -14.8% | $10.2M -27.1% | $14.0M +95.4% | $7.2M +111.7% | $3.4M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $170.0K | $0 | $0 -100.0% | $2.0K -84.6% | $13.0K | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $170.0K | $0 | $0 -100.0% | $2.0K -84.6% | $13.0K | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $8.9M -13.2% | $10.2M -27.1% | $14.0M +95.4% | $7.2M +110.9% | $3.4M | $14.7B | $3.7B | $9.6B |
| Common Stock | $0 | $0 | $0 | $0 | $0 | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$240.9M -17.1% | -$205.8M -33.2% | -$154.5M -72.1% | -$89.7M -89.4% | -$47.4M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $57.0K +83.9% | $31.0K -88.7% | $275.0K +173.5% | -$374.0K -1285.2% | -$27.0K | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 -100.0% | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $53.1M -35.2% | $81.8M -34.4% | $124.7M +30.8% | $95.4M +54.1% | $61.9M | $9.1B | $7.7B | $3.3B |
| Total Debt | $0 | $0 | $0 -100.0% | $53.0K | $0 | $724.2M | $410.6M | $399.4M |
| Net Debt | -$19.9M +6.6% | -$21.4M -36.5% | -$15.6M +42.4% | -$27.2M -124.6% | -$12.1M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Q32 Bio Inc.
NASDAQ:QTTB
$161.49M
Verrica Pharmaceuticals Inc.
NASDAQ:VRCA
$61.03M
SAB Biotherapeutics, Inc.
SABS
$31.83M
Boundless Bio, Inc.
BOLD
$31.67M
iBio, Inc.
IBIO
$26.68M
Pluri Inc.
PLUR
$20.41M
Plus Therapeutics, Inc.
PSTV
$12.12M
Intensity Therapeutics, Inc.
INTS
$6.83M
NextCure, Inc.
NXTC
$5.56M
Iterum Therapeutics plc
ITRM
$1.60M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does ANTX have?
AN2 Therapeutics, Inc. (ANTX) reported $19.94M in cash and equivalents in fiscal 2025.
How much debt does ANTX carry?
AN2 Therapeutics, Inc. (ANTX) reported $0.00 of total debt, with net debt of -$19,941,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.